Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

Tentative approval for PNT2003 positions it as the first FDA-cleared radioequivalent of Lu 177 dotatate, with anticipated ...

Unlike IMiDs, which typically induce cytostatic growth arrest, the accelerated degradation achieved by CELMoDs leads directly to cell death. This shift from stopping growth to actively killing myeloma ...

Erica Pimenta, MD, PhD, is an instructor at Harvard Medical School and physician-scientist at Dana-Farber Cancer Institute Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

Monitoring brain tumor progression is a complex balancing act between objective imaging and subjective clinical changes. In a ...

The FDA granted full approval encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

In an interview on treatments following failure of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, Rahul Banerjee, MD outlines the theory behind potential therapeutic strategies ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...